This finding provides new insights into the genetic regulation of HCV clearance and its clinical management. IL28B genotyping will be also useful for personalized CHC treatment in the forthcoming era of direct-acting antivirals. Chronic hepatitis C virus (HCV) infection represents a significant health problem worldwide with approximately 170 million people infected.[1] Over 70% of individuals acutely infected with HCV go on to develop chronic infection and are at significant risk of progressive liver fibrosis and subsequent liver cirrhosis and hepatocellular carcinoma (HCC). Antiviral treatment
has been shown to improve liver histology and decrease the incidence of HCC in chronic hepatitis Wnt inhibitor C (CHC).[2, 3] Until 2011, the standard treatment for chronic HCV infection was weekly pegylated interferon (PEG-IFN) in combination with daily doses of ribavirin (RBV); however, less than 50% of patients infected with HCV genotype 1 treated in this way achieve a sustained virological response (SVR).[4, 5] In 2009, genome-wide association studies (GWAS), including our study of HCV infection,[6] showed that a single nucleotide polymorphism (SNP) near the interleukin-28B (IL28B)
gene is strongly associated with response to PEG-IFN/RBV therapy for chronic HCV genotype 1 infection.[6-11] As a result, prediction of treatment outcome, especially nonresponsiveness to PEG-IFN/RBV, has been greatly improved by genotyping for the IL28B SNP, enabling personalized medicine to be developed for CHC. Newly developed treatments http://www.selleckchem.com/products/chir-99021-ct99021-hcl.html involving direct-acting antivirals (DAAs), including nonstructural (NS) 3/4A protease inhibitors have shown promising outcomes in combination with PEG-IFN/RBV in several clinical trials, wherein > 70% of patients infected with HCV genotype 1 achieved SVR.[12-14] Several clinical trials have revealed an association between IL28B genotype and treatment efficacy in triple therapy or IFN-free regimens.
This review focuses on the role of IL28B in CHC treatment. Various viral and host factors have been identified as significant determinants of the outcome of IFN-based treatments. Viral genotype and baseline viral load are well-known predictors of response to therapy. Other viral factors include amino FER acid substitutions at positions 70 and 91 in the HCV core region[15] and in the IFN sensitivity-determining region in NS5A[16] in patients infected with HCV genotype 1. Several host factors related to failure of treatment-induced viral clearance include older age, insulin resistance, advanced fibrosis and hepatic steatosis.[17, 18] Ethnicity is also a factor in treatment outcome. The proportion of African American patients achieving SVR on treatment with PEG-IFN/RBV is lower than Caucasian patients,[19-21] indicating that host genetic factors can be an important determinant of treatment outcome. Analysis of candidate genes has revealed an association between several host genes and spontaneous or treatment-induced clearance of HCV.
Related posts:
- 29 The likelihood of finding an antidepressant, effect, was highe
- 5%) When lopinavir fails with the emergence of the V47A mutation
- This finding might be explained by the high expression in gliobla
- p i , and to a maximal level reached at late times in the infecti
- Fesoterodine high tumor grade a finding that was also observed in the GeparQuinto study